The COVID-19 pandemic has dominated the medical literature for the past 2 years, and we have learned much about the clinical characteristics of patients with cancer that predict or are associated with severity of infection, effectiveness of vaccination in patients receiving different types of cancer therapy, and most recently, rates of breakthrough infection in previously vaccinated patients with cancer. At JAMA Oncology, we prioritized publication of COVID-19-related articles so that our readers could have the most up-to-date information to provide to patients and aid in medical decision-making. We would like to thank our authors, peer reviewers, and readers for the meaningful contributions made to the journal this past year, especially surrounding the pandemic. The JAMA Oncology editorial board, editors, and I are honored to have the opportunity to serve the oncology community by offering original, innovative, and timely scientific content that has a direct influence on researchers, clinicians, and the patients we serve. The journal’s impact factor of 31.8 placed us as one of the highest-ranking oncology journals.

Choosing the best articles for the journal was rewarding but challenging. We received a total of 3024 manuscript submissions in this past year. These submissions included 2405 research reports (Original Investigations, Brief Reports, and Research Letters) and 103 Reviews. In 2021, we published 379 articles, including 154 research, 16 Reviews, 30 Viewpoints, and 3 Special Communications. I would like to thank our authors for choosing JAMA Oncology. The quality of the published articles is reflected in the 3.7 million readers who have viewed JAMA Oncology articles.

In 2021, the overall acceptance rate for the journal was 13%. Acceptance rates for Original Investigations and Brief Reports was 6% and 11% for Research Letters. JAMA Oncology is indexed in all major databases, including PubMed/MEDLINE, Web of Science, Scopus, and many others. More detailed information about the journal’s content, reach, and impact, as well as the top read, followed, and cited articles, is displayed in the Table.1–8

The median time from the receipt of a manuscript to the first decision was 2 days without peer review and 43 days with peer review in 2021. The ability to rapidly review and return a decision on our submissions ensures that important findings are available to the oncology community as quickly as possible. We acknowledge that this task was especially difficult this year as infectious variants of COVID-19 affected our reviewers and editors.

Journal articles were amplified with Invited Commentaries, visual abstracts, and monthly audio interviews with authors.9 In addition, the JAMA Network media outreach and press releases resulted in more than 4800 media mentions of articles published in JAMA Oncology.

We are very grateful to our global consortium of peer reviewers who contributed to the journal this year. We are pleased

### Table. JAMA Oncology Statistics for 2021

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Result</th>
</tr>
</thead>
<tbody>
<tr>
<td>Manuscript data</td>
<td></td>
</tr>
<tr>
<td>All manuscripts received</td>
<td>3024</td>
</tr>
<tr>
<td>Research manuscripts received</td>
<td>2405</td>
</tr>
<tr>
<td>Acceptance rate, %</td>
<td></td>
</tr>
<tr>
<td>Overall</td>
<td>13</td>
</tr>
<tr>
<td>Research</td>
<td>6</td>
</tr>
<tr>
<td>Receipt to first decision without peer review, median, d</td>
<td>2</td>
</tr>
<tr>
<td>Receipt to first decision with peer review, median, d</td>
<td>43</td>
</tr>
<tr>
<td>Peer reviewer turnaround, median, d</td>
<td>14</td>
</tr>
<tr>
<td>Acceptance to publication, median, d</td>
<td>84</td>
</tr>
<tr>
<td>Receipt to publication, median, d</td>
<td>137</td>
</tr>
<tr>
<td>2020 Journal impact factor</td>
<td>31.8</td>
</tr>
</tbody>
</table>

### Information dissemination data

- Recipients of electronic table of contents per week: 63688
- Media mentions: 4806
- Article views and downloads: 3.7 million
- Social media followers: 81918

Top 3 articles by views/downloads

1. Adin et al,9 Association of COVID-19 mRNA Vaccine With Ipsilateral Axillary Lymph Node Reactivity on Imaging | 68752
2. Bakouy et al,2 Cancer Screening Tests and Cancer Diagnoses During the COVID-19 Pandemic | 33006
3. Rugo et al,3 Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer: A Phase 3 Randomized Clinical Trial | 30752

Top 3 articles by Altmetric score

1. Bakouy et al,2 Cancer Screening Tests and Cancer Diagnoses During the COVID-19 Pandemic | 1976
2. Global Burden of Disease 2019 Cancer Collaboration,6 Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life Years for 29 Cancer Groups From 2010 to 2019: A Systematic Analysis for the Global Burden of Disease Study 2019 | 892
3. Thomson et al,3 Association of Smoking Initiation and Cessation Across the Life Course and Cancer Mortality: Prospective Study of 410 000 US Adults | 882

Top 3 articles by Web of Science citations

1. Wang et al,4 Analyses of Risk, Racial Disparity, and Outcomes Among US Patients With Cancer and COVID-19 Infection | 74
2. Pinter et al,2 The Current Landscape of Immune Checkpoint Blockade in Hepatocellular Carcinoma: A Review | 48
3. Massarweh et al,4 Evaluation of Seropositivity Following BNT162b2 Messenger RNA Vaccination for SARS-CoV-2 in Patients Undergoing Treatment for Cancer | 42

---

Data based on all manuscripts submitted, including research, review and education, opinion, and letters.

Includes Original Investigations, Brief Reports, and Research Letters.
to acknowledge their contributions to JAMA Oncology by publishing the names of the hundreds of experts who completed a manuscript review in 2021. This group of renowned laboratory, clinical, quantitative, and statistical scientists rapidly provided comprehensive reviews of the submitted manuscripts. We would not be able to provide this service without our expert peer reviewers and their commitment to providing prompt and high-quality reviews for the journal. We thank you.

Finally, we would like to thank our readers. We provide our table of contents of newly published content each week, by email, to nearly 64,000 readers. If you currently do not receive JAMA Oncology table of contents by email, you can sign up at http://www.jamaoncology.com. We are proud to continue offering provocative and timely research for scientists, clinicians, and trainees in the field of oncology worldwide. We encourage our readers to stay involved with the journal by submitting Letters to the Editor and sending us recommendations for new topics that you would like to see covered in future issues. Your suggestions make this interdisciplinary oncology journal dynamic and current.

We have truly enjoyed being involved in JAMA Oncology's continued success this year, and we look forward to the year ahead. We could not have done it without you. We invite all of our readers to follow us on Twitter @JAMAOnco or friend us on Facebook along with a community of more than 81,000 people. We will keep you up to date on the most important discoveries influencing cancer care.

ARTICLE INFORMATION
Author Affiliations: Editor, JAMA Oncology; University of Washington, Fred Hutchinson Cancer Research Center, Seattle.
Corresponding Author: Mary L. (Nora) Disis, MD, University of Washington, Fred Hutchinson Cancer Research Center, 850 Republican St, Brotman 221, Box 358050, Seattle, WA 98195 (ndisis@uw.edu).
Published Online: March 24, 2022. doi:10.1001/jamaoncol.2022.0262
Conflict of Interest Disclosures: Dr Disis reported personal fees for serving as the Editor of JAMA Oncology, shares as the founder of EpiThany, and grants from Pfizer, Precigen, Bavarian Nordic, and Veanna.

REFERENCES